Metoclopramide Pilot Trial

Gastroschisis Clinical Trial

Official title:

The Use of Metoclopramide vs. Placebo in Infants With Gastroschisis. A Pilot Double Blind Randomized Controlled Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02098915
• Other study ID #: 1000038585
• Secondary ID: 169334
• Status: Terminated
• Phase: Phase 3
• Start date: March 2014
• Est. completion date: December 12, 2019

Study information

• Verified date: December 2019
• Source: The Hospital for Sick Children
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Infants with gastroschisis typically have poor intestinal motility for the first weeks to months after birth. Prokinetic agents are often used in these infants to improve intestinal motility in an attempt to quicken the attainment of enteric feeds. However, the evidence to support this practice remains weak. Investigators hypothesize that a prokinetic agent given intravenously (infused into a vein) may be effective in improving gut motility in children with gastroschisis.

Description:

The research question will be addressed in a pilot randomized double-blind placebo controlled clinical trial evaluating the efficacy of metoclopramide.Investigators will recruit 30 neonates (15 per arm) diagnosed with gastroschisis. There will be two arms to the trial: the experimental arm will receive intravenous metoclopramide and the control arm will receive placebo. Patients will receive prokinetic agent therapy, dosed according to weight, or placebo. Each subject will receive the intervention for 28 days or until achievement of full enteral feeding, whichever comes first. Primary outcome: Days to achieve full enteral feeding when all intake (at least 150 ml/kg/day for 72 hours) is given as breast milk or formula by gavage or by mouth. Secondary outcomes: 1. Duration (days) until initiation of enteral feeds.

2. Duration (days) on parenteral nutrition. 3. Weight gain, measured by grams per day per week during therapy. 4. Occurrence of adverse effects associated with the use of metoclopramide. 5. Rate of catheter-related sepsis episodes (line positive blood cultures necessitating antibiotic treatment or catheter removal). 6. Incidence of necrotizing enterocolitis (NEC) based on clinical criteria and presence of pneumatosis intestinalis on an abdominal X-ray. 7. Duration of hospitalization (number of days from admission until final hospital discharge).

Subjects can be withdrawn from the study if meet one of the following criteria:

• Subject develops extrapyramidal symptoms

• Subject has not established full enteral feeding by the end of day 28 of therapy

• Withdrawal of informed consent or refusal of further study participation by parent/legal guardian

• Serious adverse event which, in the opinion of the investigator, indicates that continued participation in the study is not in the best interest of the subject

• Any clinical adverse event, laboratory abnormality or intercurrent illness which, in the opinion of the investigator, indicates that continued participation in the study is not in the best interest of the subject

• Unpredictable discontinuation of metoclopramide drug supply

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: December 12, 2019
• Est. primary completion date: December 12, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 33 Weeks and older

Eligibility

Inclusion Criteria:

1. Diagnosis of uncomplicated neonatal gastroschisis treated by primary fascial closure or delayed closure using a pre-formed silo (fascial closure or plastic closure)

2. Expectation of the treating physician that the patient will require intravenous therapy for at least 7 days post-enrolment

Exclusion Criteria:

1. Presence of other significant congenital malformation (ie life-threatening, requiring surgical intervention, or having an effect on intestinal motility)

2. Presence of intestinal atresia, intestinal necrosis or intestinal perforation (ie complicated gastroschisis)

3. Gestational age <32 weeks

4. Birth weight < 1500 gm

5. Received an investigational product within the past 30 days

Related Conditions & MeSH terms

• Gastroschisis

Intervention

Drug:
• intravenous metoclopramide
the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age

Other:
• Placebo
equivalent volume to intravenous metoclopramide (dosed according to the current Sick Kids guidelines based upon weight and age ) of sterile sodium chloride 0.9% injection as a placebo

Locations

Country	Name	City	State
Canada	The Hospital for Sick Children	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
The Hospital for Sick Children	The Physicians' Services Incorporated Foundation

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Days to achieve full enteral feeding	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Days to achieve full enteral feeding will be recorded when all intake (at least 150 ml/kg/day for 72 hours) is given as breast milk or formula by gavage or by mouth	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary	Duration until initiation of enteral feeds	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Duration (days) until initiation of enteral feeds will be recorded	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary	Duration on parenteral nutrition	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Duration (days) on parenteral nutrition will be recorded	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary	Weight gain	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Weight gain, measured by grams per day per week during therapy will be recorded	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary	Occurrence of adverse effects	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Occurrence of adverse effects associated with the use of metoclopramide will be recorded.	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary	Rate of catheter-related sepsis episodes	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Rate of catheter-related sepsis episodes during intravenous treatment (line positive blood cultures necessitating antibiotic treatment or catheter removal) will be recorded.	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary	Incidence of necrotizing enterocolitis (NEC)	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Incidence of necrotizing enterocolitis (NEC) during the therapy based on clinical criteria and presence of pneumatosis intestinalis on an abdominal X-ray will be recorded.	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Secondary	Duration of hospitalization	Duration of hospitalization (number of days from admission until final hospital discharge) will be recorded.	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks